Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant
This article was originally published in The Pink Sheet Daily
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.
You may also be interested in...
Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.
A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.
The asset-focused operator of virtual biotechs teamed with Texas early-stage investment group Remeditex to back a new entity. Tigercat has filed an IND to investigate serlopitant for chronic itching.